(Bloomberg) -- Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators ... based on research showing the medicine, called inavolisib, could ...

Swiss pharma company Roche ... FDA Priority Review status for a Perjeta (pertuzumab) regimen to be used before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast cancer ... was accepted for FDA review in February.

The US Food and Drug Administration (FDA) has granted Roche a breakthrough therapy designation for its breast cancer therapy inavolisib ... the evaluation and review processes for certain therapies.

Foundation Medicine has developed the capability for high-throughput NGS analysis of genomic alterations covering more than 300 cancer ... for two Roche molecules, approved by the FDA and EMA ...

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer. Among patients with liver-dominant metastatic ...

Breast Cancer Congress Basel, 13 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science ...

Roche announced that ... scoring methods. “This FDA Breakthrough Device Designation underscores the potential of our computational pathology platform to enable more personalised treatment decisions ...

A study involving an experimental cancer drug being developed by Roche ... HER2-positive breast cancer," said Kimberly Blackwell, the study's lead researcher and a professor of medicine at Duke ...

Roche received FDA clearance last year for the test to be used in the United States. More than 90% of cervical cancer cases are caused by HPV, according to the U.S. Centers for Disease Control and ...